Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-methoxycoumarin-3-carboxamide is a synthetic coumarin-based small molecule investigated for its potential therapeutic application in hepatocellular carcinoma (HCC). It serves as the parent scaffold for a novel series of N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides designed to target liver cancer cells. The compound demonstrates moderate antiproliferative activity against HepG2 cells, while its derivatives, such as the 5-bromo analogue (Compound 5), exhibit significantly higher potency. Its mechanism of action involves the activation of executioner caspases (Caspase-3 and Caspase-7) and the inhibition of β-tubulin polymerization. By disrupting microtubule dynamics and triggering the apoptotic pathway, the compound induces cell cycle arrest (typically in the G1/S or G2/M phases) and programmed cell death in neoplastic cells with minimal impact on normal healthy cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-methoxycoumarin-3-carboxamide.